Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): Asystematic review

Clinical Nutrition

Volumn 32, Issue 6, 2013, Pages 888-893

  Schloss, Janet M ^a   Colosimo, Maree ^a,b   Airey, Caroline ^c   Masci, Paul P ^a   Linnane, Anthony W ^a   Vitetta, Luis ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Hematology and Oncology Clinics of Australia   (Australia)

^c QUEENSLAND HEALTH   (Australia)

Author keywords

Chemotherapy induced peripheral neuropathy; CIPN; Nutraceuticals; Vitamins

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; BORTEZOMIB; CALCIUM; CARBOPLATIN; CISPLATIN; EPOTHILONE DERIVATIVE; FLUOROURACIL; GLUTAMINE; GLUTATHIONE; LEVACECARNINE; MAGNESIUM; NUTRACEUTICAL; OMEGA 3 FATTY ACID; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEASOME INHIBITOR; PYRIDOXINE; TAXANE DERIVATIVE; THALIDOMIDE; THIOCTIC ACID; VINCA ALKALOID; VINCRISTINE;

ALCOHOLISM; ALLERGIC REACTION; ATHEROSCLEROSIS; CACHEXIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CARPAL TUNNEL SYNDROME; CYANOCOBALAMIN DEFICIENCY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; INSOMNIA; LIVER FAILURE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NERVE CONDUCTION; NERVE FIBER; NEUROTOXICITY; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OTOTOXICITY; PARANEOPLASTIC SYNDROME; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; STOMATITIS; SURAL NERVE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THYROID DISEASE; VITAMIN SUPPLEMENTATION; WEAKNESS;

CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CIPN; NUTRACEUTICALS; VITAMINS;

ACETYLCARNITINE; ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; GLUTAMINE; GLUTATHIONE; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOCTIC ACID; TRACE ELEMENTS; VITAMINS;

EID: 84887628724     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2013.04.007     Document Type: Review

References (43)

1. Visovsky C., Meyer R.R., Roller J., Poppas M. Evaluation and management of peripheral neuropathy in diabetic patients with cancer. Clin J Oncol Nurs 2008, 12:243-247.
2. Armstrong T., Almadrones L., Gilbert M.R. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 2005, 32:305-311.
3. Cavaletti G., Nicolini G., Marmiroli P. Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies. Front Biosci 2008, 13:3506-3524.
4. Cavaletti G., Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Expert Opin Drug Saf 2004, 3:535-546.
5. Bhagra A., Roa R.D. Chemotherapy-induced neuropathy. Curr Oncol Rep 2007, 9:290-299.
6. Park S.B., Krishnan A.V., Lin C.S.Y., Goldstein D., Friedlander M., Kiernan M.C., et al. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008, 15:3081-3094.
7. Schiff D., Wen P.Y., van den Bent M.J. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009, 6:596-603.
8. Pirzada N.A., Ali I.I., Dafer R.M. Fluorouracil-induced neurotoxicity. Ann Pharmacother 2000, 34:35-38.
9. National Health and Medical Research Council NHMRC additional levels of evidence and grades for recommendations for developers of guidelin. es. Commonwealth of Australia 2009, National Health and Medical Research Council.
10. Gamelin L., Boisdron-Celle M., Delva R., Guerin-Meyer V., Ifrah N., Morel A., et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10(12 I):4055-4061.
11. Hochster H.S., Grothey A., Childs B.H. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. JClin Oncol 2007, 25(25):4028-4029.
12. Muto O., Ando H., Ono T., Itagaki H., Kobayashi Y., Onuki M., et al. Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions. Gan To Kagaku Ryoho 2007, 34(4):579-581.
13. Ishibashi K., Okada N., Miyazaki T., Sano M., Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 2010, 15(1):82-87.
14. Pace A., Antonella S., Mauro P., Vittoria M., Umberto P., Girolamo Del M., et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. Source J Clin Oncol 2003, 21(5):927-931.
15. Argyriou A.A., Chroni E., Koutras A., Ellul J., Papapetropoulos S., Katsoulas G., et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005, 64(1):26-31.
16. Argyriou A.A., Chroni E., Kourtras A., Iconomou G., Papapetropoulos S., Polychronopoulos P., et al. Arandomised controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer 2006, 14:1134-1140.
17. Pace A., Giannarelli D., Galie E., Savarese A., Carpano S., Della Giulia M., et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology 2010, 74(9):762-766.
18. Kottschade L.A., Sloan J.A., Mazurczak M.A., Johnson D.B., Murphy B.P., Rowland K.M., et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer 2010.
19. Paksoy M., Ayduran E., Sanli A., Enken M., Aydin S., Oktay Z.A. The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats. Med Oncol 2011, 28(2):615-621.
20. Gedlicka C., Scheithauer W., Schull B., Kornek G.V. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. JClin Oncol 2002, 20(15):3359-3361.
21. Lin P.C., Lee M.Y., Wang W.S., Yen C.C., Chao T.C., Hsiao L.T., et al. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer 2006, 14:484-487.
22. Pachman D.R., Barton D.L., Watson J.C., Loprinzi C.L. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 2011, 90(3):377-387.
23. Cascinu S., Cordella L., Del Ferro E., Fronzoni M., Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo- controlled trial. JClin Oncol 1995, 13(1):26-32.
24. Colombo N., Bini S., Miceli D., Bogliun G., Marzorati L., Cavaletti G., et al. Weekly cisplatin+/- glutathione in relapsed ovarian carcinoma. Int J Gynecol Cancer 1995, 5(2):81-86.
25. Smyth J.F., Bowman A., Perren T., Wilkinson P., Prescott R.J., Quinn K.J., et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 1997, 8(6):569-573.
26. Cascinu S., Catalano V., Cordella L., Labianca R., Giordani P., Baldelli A.M., et al. Neuroprotective effect ofreduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. JClin Oncol 2002, 20(16):3478-3483.
27. Milla P., Airoldi M., Weber G., Drescher A., Jaehde U., Cattel L. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anti-Cancer Drug 2009, 20(5):396-402.
28. Vahdat L., Papadopoulos K., Lange D., Leuin S., Kaufman E., Donovan D., et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001, 7(5):1192-1197.
29. Subblefield M.D., Vahdat L.T., Balmaceda C.M., Troxel A.B., Hesdorffer C.S., Gooch C.L. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol 2005, 17(4):271-276.
30. Wang W.S., Lin J.K., Lin T.C., Chen W.S., Jiang J.K., Wang H.S., et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007, 12(3):312-319.
31. Bianchi G., Vitali G., Caraceni A., Ravaglia S., Capri G., Cundari S., et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005, 41(12):1746-1750.
32. Maestri A., De Pasquale Ceratti A., Cundari S., Zanna C., Cortesi E., Crino L. Apilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005, 91(2):135-138.
33. Hershman D.L., Unger J.M., Crew K.D., Moinpour C., Minasian L.M., Hansen L., et al. Randomized placebo-controlled trial of acetyl-L-carnitine for prevention of taxane-induced neuropathy during adjuvant breast cancer therapy. JClin Oncol 2012, Suppl.:abstr 9018.
34. Wiernik P.H., Yeap B., Vogl S.E., Kaplan B.H., Comis R.L., Falkson G., et al. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 1992, 10(1):1-9.
35. Ghoreishi Z., Esfahani A., Djazayeri A., Djalali M., Golestan B., Ayromlou H., et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomised double-blind placebo controlled trial. BMC Cancer 2012, 12:355.
36. Garg M.B., Ackland S. Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect. Cancer Chemother Pharmacol 2010.
37. Cavaletti G., Frigeni B., Lanzani F., Mattavelli L., Susani E., Alberti P., et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 2010, 46(3):479-494.
38. Smith E.M., Beck S.L., Cohen J. The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 2008, 35(1):96-102.
39. Park S.B., Lin C.S., Kiernan M.C. Nerve excitability assessment in chemothereapy-induced neurotoxicity. JVis Exp 2012, 62:3439.
40. Dunlap B., Paice J.A. Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. JSupport Oncol 2006, 4(8):398-399.
41. Visovsky C., Daly B.J. Clinical evaluation and patterns of chemotherapy-induced peripheral neuropathy. JAm Acad Nurse Pract 2004, 16(8):353-359.
42. Hughes R. NCI-CTC vs TNS: which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy?. Nat Clin Pract Neurol 2008, 4(2):68-69.
43. Cavaletti G., Frigeni B., Lanzani F., Pitti M., Rota S., Briani C., et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. JPeripher Nerv Syst 2007, 12(3):210-215.